Lataa...
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
BACKGROUND: Dual pathway inhibition with 2.5 mg rivaroxaban twice daily plus 100 mg aspirin once daily may be a promising alternative to 100 mg aspirin antiplatelet therapy for the prevention of cardiovascular events in patients with coronary artery disease and/or peripheral arterial disease. Howeve...
Tallennettuna:
| Julkaisussa: | Eur J Prev Cardiol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7457457/ https://ncbi.nlm.nih.gov/pubmed/32223323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2047487320913380 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|